<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>Patient Summary Dashboard - STEVENS, ROBERT</title>
<style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 10px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.2);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #5a67d8 0%, #4c51bf 100%);
            color: white;
            padding: 30px;
            text-align: center;
        }
        
        .header h1 {
            font-size: 32px;
            margin-bottom: 10px;
        }
        
        .header p {
            font-size: 14px;
            opacity: 0.9;
        }
        
        .patient-info {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            padding: 30px;
            background: #ebf4ff;
            border-bottom: 3px solid #90cdf4;
        }
        
        .info-card {
            background: white;
            padding: 20px;
            border-radius: 8px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.1);
            border-left: 4px solid #4299e1;
        }
        
        .info-card h3 {
            color: #2d3748;
            font-size: 14px;
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 10px;
        }
        
        .info-card p {
            font-size: 18px;
            font-weight: 600;
            color: #4a5568;
        }
        
        .content {
            padding: 30px;
        }
        
        .section {
            margin-bottom: 40px;
        }
        
        .section h2 {
            color: #2d3748;
            font-size: 24px;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 2px solid #e2e8f0;
        }
        
        .diagnosis-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 15px;
        }
        
        .diagnosis-item {
            background: #ebf8ff;
            border-left: 4px solid #4299e1;
            padding: 15px;
            border-radius: 5px;
        }
        
        .diagnosis-item.chronic {
            background: #fffaf0;
            border-left-color: #ed8936;
        }
        
        .diagnosis-item h4 {
            color: #2d3748;
            margin-bottom: 8px;
        }
        
        .diagnosis-item p {
            font-size: 14px;
            color: #718096;
            margin-bottom: 4px;
        }
        
        .alert {
            background: #fef5e7;
            border-left: 4px solid #f39c12;
            padding: 15px;
            margin: 20px 0;
            border-radius: 5px;
        }
        
        .alert h4 {
            color: #d68910;
            margin-bottom: 8px;
        }
        
        .alert p {
            color: #7c5d10;
            font-size: 14px;
        }
        
        .timeline {
            position: relative;
            padding-left: 40px;
        }
        
        .timeline::before {
            content: '';
            position: absolute;
            left: 10px;
            top: 0;
            bottom: 0;
            width: 2px;
            background: #cbd5e0;
        }
        
        .timeline-item {
            position: relative;
            margin-bottom: 30px;
            padding-left: 20px;
        }
        
        .timeline-item::before {
            content: '';
            position: absolute;
            left: -34px;
            top: 5px;
            width: 12px;
            height: 12px;
            border-radius: 50%;
            background: #4299e1;
            border: 3px solid white;
            box-shadow: 0 0 0 2px #4299e1;
        }
        
        .timeline-item.critical::before {
            background: #f56565;
            box-shadow: 0 0 0 2px #f56565;
        }
        
        .timeline-date {
            font-weight: 600;
            color: #4299e1;
            margin-bottom: 5px;
        }
        
        .timeline-content {
            background: #f7fafc;
            padding: 15px;
            border-radius: 5px;
            border: 1px solid #e2e8f0;
        }
        
        .timeline-content h4 {
            color: #2d3748;
            margin-bottom: 8px;
        }
        
        .timeline-content p {
            font-size: 14px;
            color: #4a5568;
            line-height: 1.6;
            margin-bottom: 6px;
        }
        
        .lab-table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 15px;
        }
        
        .lab-table th {
            background: #4c51bf;
            color: white;
            padding: 12px;
            text-align: left;
            font-weight: 600;
        }
        
        .lab-table td {
            padding: 10px 12px;
            border-bottom: 1px solid #e2e8f0;
        }
        
        .lab-table tr:hover {
            background: #ebf8ff;
        }
        
        .lab-table td strong {
            font-weight: 700;
            color: #2d3748;
        }
        
        .status-badge {
            display: inline-block;
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .status-normal {
            background: #c6f6d5;
            color: #22543d;
        }
        
        .status-abnormal {
            background: #fed7d7;
            color: #742a2a;
        }
        
        .status-elevated {
            background: #feebc8;
            color: #7c2d12;
        }
        
        .followup-list {
            background: #f7fafc;
            padding: 20px;
            border-radius: 8px;
            border: 1px solid #e2e8f0;
        }
        
        .followup-list ul {
            list-style: none;
            padding-left: 0;
        }
        
        .followup-list li {
            padding: 8px 0;
            padding-left: 25px;
            position: relative;
            color: #4a5568;
        }
        
        .followup-list li::before {
            content: '‚úì';
            position: absolute;
            left: 0;
            color: #48bb78;
            font-weight: bold;
        }
        
        .appointment-card {
            background: white;
            border: 1px solid #e2e8f0;
            border-left: 4px solid #4299e1;
            padding: 15px;
            margin-bottom: 10px;
            border-radius: 5px;
        }
        
        .appointment-card h4 {
            color: #2d3748;
            margin-bottom: 5px;
        }
        
        .appointment-card p {
            font-size: 14px;
            color: #718096;
        }
        
        .footer {
            background: #2d3748;
            color: white;
            text-align: center;
            padding: 20px;
            font-size: 12px;
        }
        
        @media print {
            body {
                background: white;
                padding: 0;
            }
            .container {
                box-shadow: none;
            }
        }
    </style>
</head>
<body>
<div class="container">
<div class="header">
<h1>PATIENT MEDICAL SUMMARY</h1>
<p>Metropolitan Cancer Center | Hematology-Oncology Department</p>
<p>Generated: November 15, 2024 | Report ID: EHR-2024-11-789321</p>
</div>
<div class="patient-info">
<div class="info-card">
<h3>Patient Name</h3>
<p>STEVENS, ROBERT</p>
</div>
<div class="info-card">
<h3>Medical Record Number</h3>
<p>MRN-2024-789321</p>
</div>
<div class="info-card">
<h3>Date of Birth</h3>
<p>03/25/1977 (47 years)</p>
</div>
<div class="info-card">
<h3>Sex</h3>
<p>Male</p>
</div>
<div class="info-card">
<h3>Primary Physician</h3>
<p>Dr. Michael Chen, MD</p>
</div>
<div class="info-card">
<h3>Last Visit</h3>
<p>11/15/2024</p>
</div>
</div>
<div class="content">
<!-- Active Diagnoses -->
<div class="section">
<h2>üî¥ Active &amp; Chronic Diagnoses</h2>
<div class="diagnosis-list">
<div class="diagnosis-item">
<nav><a href="#diffuse-large-b-cell-lymphoma">Diffuse Large B-Cell Lymphoma (Active)</a></nav>
<p><strong>Subtype:</strong> Germinal Center B-cell-like (GCB)</p>
<p><strong>Stage:</strong> Stage IIB (Ann Arbor)</p>
<p><strong>Involvement:</strong> Left cervical and supraclavicular lymph nodes</p>
<p><strong>Largest Node:</strong> 2.6 cm (left cervical chain)</p>
<p><strong>Ki-67:</strong> 70% (high proliferation)</p>
<p><strong>Diagnosed:</strong> January 2024</p>
<p><strong>Status:</strong> Treatment planning - R-CHOP chemotherapy</p>
</div>
<div class="diagnosis-item">
<nav><a href="#b-symptoms">B-Symptoms (Present)</a></nav>
<p><strong>Night Sweats:</strong> 2-3 nights per week, drenching</p>
<p><strong>Fever:</strong> Intermittent low-grade</p>
<p><strong>Weight Loss:</strong> 5 kg over 3 months (unintentional)</p>
<p><strong>Significance:</strong> Indicates Stage B disease, impacts prognosis</p>
</div>
<div class="diagnosis-item">
<nav><a href="#prognostic-assessment">Prognostic Assessment</a></nav>
<p><strong>IPI Score:</strong> 1 (Low-intermediate risk)</p>
<p><strong>Age:</strong> &lt;60 years (favorable)</p>
<p><strong>Stage:</strong> II (favorable)</p>
<p><strong>LDH:</strong> Elevated (unfavorable)</p>
<p><strong>ECOG PS:</strong> 1 (favorable)</p>
<p><strong>Extranodal Sites:</strong> 0 (favorable)</p>
</div>
</div>
<div class="alert">
<h4>‚ö†Ô∏è Molecular Testing Complete</h4>
<p>GCB subtype confirmed by IHC (Hans algorithm). FISH testing negative for MYC/BCL2/BCL6 rearrangements - NOT Double-Hit or Triple-Hit lymphoma. Standard R-CHOP therapy appropriate.</p>
</div>
</div>
<!-- Treatment Timeline -->
<div class="section">
<h2>üìÖ Treatment Timeline</h2>
<div class="timeline">
<div class="timeline-item">
<div class="timeline-date">June 2023</div>
<div class="timeline-content">
<h4>Initial Symptom Onset</h4>
<p><strong>Details:</strong> Patient noticed small painless lump in left neck. No other symptoms at the time.</p>
<p><strong>Action:</strong> Monitored by patient, no medical evaluation sought initially</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">October 2023</div>
<div class="timeline-content">
<h4>Symptom Progression</h4>
<p><strong>Details:</strong> Left neck mass increased in size. New onset of night sweats (2-3x per week, drenching). Fatigue worsening.</p>
<p><strong>Action:</strong> Patient presented to primary care physician</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">October 20, 2023</div>
<div class="timeline-content">
<h4>Primary Care Evaluation</h4>
<p><strong>Physical Exam:</strong> 2.5 cm firm, mobile, non-tender left cervical lymph node. Additional smaller nodes palpable in left supraclavicular region.</p>
<p><strong>Labs Ordered:</strong> CBC, CMP, LDH</p>
<p><strong>Imaging:</strong> Neck ultrasound ordered</p>
<p><strong>Outcome:</strong> Referral to hematology-oncology</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">October 28, 2023</div>
<div class="timeline-content">
<h4>Initial Lab Results</h4>
<p><strong>LDH:</strong> 340 U/L (elevated, normal 140-280)</p>
<p><strong>Hemoglobin:</strong> 12.1 g/dL (mild anemia)</p>
<p><strong>WBC:</strong> 8.2 K/uL (normal)</p>
<p><strong>Outcome:</strong> Elevated LDH concerning for lymphoproliferative disorder</p>
</div>
</div>
<div class="timeline-item" id="prognostic-assessment">
<div class="timeline-date">November 5, 2023</div>
<div class="timeline-content">
<h4>Neck Ultrasound</h4>
<p><strong>Findings:</strong> Multiple enlarged lymph nodes in left cervical and supraclavicular chains. Largest measures 2.6 cm. Loss of normal fatty hilum, rounded morphology.</p>
<p><strong>Assessment:</strong> Highly suspicious for lymphoma</p>
<p><strong>Outcome:</strong> Excisional biopsy recommended</p>
</div>
</div>
<div class="timeline-item critical">
<div class="timeline-date">November 18, 2023</div>
<div class="timeline-content">
<h4>Excisional Lymph Node Biopsy</h4>
<p><strong>Procedure:</strong> Excisional biopsy of left cervical lymph node under local anesthesia</p>
<p><strong>Pathology:</strong> Diffuse Large B-Cell Lymphoma (DLBCL)</p>
<p><strong>Subtype:</strong> Germinal Center B-cell-like (GCB) by IHC</p>
<p><strong>Ki-67:</strong> ~70%</p>
<p><strong>Outcome:</strong> Diagnosis confirmed - DLBCL</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">December 5, 2023</div>
<div class="timeline-content">
<h4>PET/CT Staging</h4>
<p><strong>Findings:</strong> FDG-avid lymphadenopathy in left cervical and supraclavicular chains (SUVmax 12.5). No infradiaphragmatic or extranodal involvement.</p>
<p><strong>Stage:</strong> Stage IIB (Ann Arbor) - B symptoms present</p>
<p><strong>Outcome:</strong> Limited stage disease, excellent prognosis with R-CHOP</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">December 12, 2023</div>
<div class="timeline-content">
<h4>Bone Marrow Biopsy</h4>
<p><strong>Procedure:</strong> Bilateral posterior iliac crest bone marrow aspiration and biopsy</p>
<p><strong>Pathology:</strong> Negative for lymphoma involvement</p>
<p><strong>Outcome:</strong> No bone marrow involvement confirmed</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">December 20, 2023</div>
<div class="timeline-content">
<h4>FISH Testing Results</h4>
<p><strong>MYC Rearrangement:</strong> Negative</p>
<p><strong>BCL2 Rearrangement:</strong> Negative</p>
<p><strong>BCL6 Rearrangement:</strong> Negative</p>
<p><strong>Interpretation:</strong> NOT Double-Hit or Triple-Hit lymphoma</p>
<p><strong>Outcome:</strong> Standard R-CHOP appropriate (no need for dose-intensified regimen)</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">January 8, 2024</div>
<div class="timeline-content">
<h4>Baseline Echocardiogram</h4>
<p><strong>Purpose:</strong> Baseline cardiac function assessment prior to anthracycline (doxorubicin) therapy</p>
<p><strong>LVEF:</strong> 62% (normal)</p>
<p><strong>Outcome:</strong> No contraindication to R-CHOP therapy</p>
</div>
</div>
<div class="timeline-item critical">
<div class="timeline-date">January 15, 2024</div>
<div class="timeline-content">
<h4>R-CHOP Cycle 1 - Day 1</h4>
<p><strong>Regimen:</strong> Rituximab 375 mg/m¬≤, Cyclophosphamide 750 mg/m¬≤, Doxorubicin 50 mg/m¬≤, Vincristine 1.4 mg/m¬≤ (max 2 mg), Prednisone 100 mg PO days 1-5</p>
<p><strong>Premedications:</strong> Antiemetics (ondansetron, dexamethasone), allopurinol for tumor lysis prophylaxis</p>
<p><strong>Tolerability:</strong> Infusion completed without complications</p>
<p><strong>Outcome:</strong> Cycle 1 initiated successfully</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">February 5, 2024</div>
<div class="timeline-content">
<h4>R-CHOP Cycle 2 - Day 1</h4>
<p><strong>Details:</strong> Second cycle administered per protocol</p>
<p><strong>Side Effects:</strong> Mild nausea (controlled with antiemetics), fatigue, mild peripheral neuropathy</p>
<p><strong>Physical Exam:</strong> Left neck mass significantly smaller, no longer palpable</p>
<p><strong>Outcome:</strong> Excellent clinical response</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">February 26, 2024</div>
<div class="timeline-content">
<h4>R-CHOP Cycle 3 - Day 1</h4>
<p><strong>Details:</strong> Third cycle administered per protocol</p>
<p><strong>Side Effects:</strong> Cumulative fatigue, worsening peripheral neuropathy (grade 1-2)</p>
<p><strong>Outcome:</strong> Tolerating treatment well</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">March 20, 2024</div>
<div class="timeline-content">
<h4>Interim PET/CT (After Cycle 3)</h4>
<p><strong>Findings:</strong> Complete metabolic response. No residual FDG-avid disease. Deauville Score 1-2.</p>
<p><strong>Interpretation:</strong> Excellent response to therapy</p>
<p><strong>Outcome:</strong> Continue R-CHOP for total of 6 cycles as planned</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">April 10, 2024</div>
<div class="timeline-content">
<h4>R-CHOP Cycle 4 - Day 1</h4>
<p><strong>Details:</strong> Fourth cycle administered per protocol</p>
<p><strong>Side Effects:</strong> Manageable, no dose modifications required</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">May 1, 2024</div>
<div class="timeline-content">
<h4>R-CHOP Cycle 5 - Day 1</h4>
<p><strong>Details:</strong> Fifth cycle administered per protocol</p>
<p><strong>Side Effects:</strong> Persistent peripheral neuropathy (grade 2), fatigue</p>
</div>
</div>
<div class="timeline-item critical">
<div class="timeline-date">May 22, 2024</div>
<div class="timeline-content">
<h4>R-CHOP Cycle 6 - Day 1 (Final Cycle)</h4>
<p><strong>Details:</strong> Sixth and final cycle administered per protocol</p>
<p><strong>Status:</strong> Treatment completion celebrated with patient and family</p>
<p><strong>Outcome:</strong> All 6 cycles of R-CHOP completed successfully</p>
</div>
</div>
<div class="timeline-item">
<div class="timeline-date">July 10, 2024</div>
<div class="timeline-content">
<h4>End-of-Treatment PET/CT</h4>
<p><strong>Findings:</strong> Complete metabolic response maintained. No evidence of residual or recurrent disease. Deauville Score 1.</p>
<p><strong>Interpretation:</strong> Complete remission achieved</p>
<p><strong>Outcome:</strong> Excellent outcome, transition to surveillance</p>
</div>
</div>
<div class="timeline-item" id="b-symptoms">
<div class="timeline-date">November 15, 2024</div>
<div class="timeline-content">
<h4>Current Visit - 4-Month Post-Treatment Follow-up</h4>
<p><strong>Details:</strong> Patient doing very well. B-symptoms completely resolved. Energy level returning to normal.</p>
<p><strong>Physical Exam:</strong> No palpable lymphadenopathy. No hepatosplenomegaly.</p>
<p><strong>Labs:</strong> LDH 195 U/L (normal). CBC normal.</p>
<p><strong>Outcome:</strong> Continue surveillance, follow-up in 3 months</p>
</div>
</div>
</div>
</div>
<!-- Recent Labs -->
<div class="section">
<h2>üî¨ Most Recent Laboratory Results (11/15/2024)</h2>
<table class="lab-table">
<thead>
<tr>
<th>Test</th>
<th>Result</th>
<th>Units</th>
<th>Reference Range</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDH (Lactate Dehydrogenase)</td>
<td><strong>195</strong></td>
<td>U/L</td>
<td>140-280</td>
<td><span class="status-badge status-normal">Normal (normalized)</span></td>
</tr>
<tr>
<td>Hemoglobin</td>
<td><strong>14.2</strong></td>
<td>g/dL</td>
<td>13.5-17.5</td>
<td><span class="status-badge status-normal">Normal</span></td>
</tr>
<tr>
<td>WBC</td>
<td><strong>6.8</strong></td>
<td>K/uL</td>
<td>4.5-11.0</td>
<td><span class="status-badge status-normal">Normal</span></td>
</tr>
<tr>
<td>ANC (Absolute Neutrophil Count)</td>
<td><strong>4.2</strong></td>
<td>K/uL</td>
<td>1.5-8.0</td>
<td><span class="status-badge status-normal">Normal</span></td>
</tr>
<tr>
<td>Platelet</td>
<td><strong>245</strong></td>
<td>K/uL</td>
<td>150-400</td>
<td><span class="status-badge status-normal">Normal</span></td>
</tr>
<tr>
<td>Creatinine</td>
<td><strong>0.9</strong></td>
<td>mg/dL</td>
<td>0.7-1.3</td>
<td><span class="status-badge status-normal">Normal</span></td>
</tr>
<tr>
<td>ALT</td>
<td><strong>32</strong></td>
<td>U/L</td>
<td>7-56</td>
<td><span class="status-badge status-normal">Normal</span></td>
</tr>
<tr>
<td>Uric Acid</td>
<td><strong>5.2</strong></td>
<td>mg/dL</td>
<td>3.5-7.2</td>
<td><span class="status-badge status-normal">Normal</span></td>
</tr>
</tbody>
</table>
</div>
<!-- Current Medications -->
<div class="section">
<h2>üíä Current Medications</h2>
<table class="lab-table">
<thead>
<tr>
<th>Medication</th>
<th>Dose</th>
<th>Frequency</th>
<th>Indication</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabapentin</td>
<td>300 mg PO</td>
<td>Three times daily</td>
<td>Chemotherapy-induced peripheral neuropathy</td>
<td><span class="status-badge status-normal">Active</span></td>
</tr>
<tr>
<td>Vitamin B Complex</td>
<td>1 tablet PO</td>
<td>Daily</td>
<td>Neuropathy support</td>
<td><span class="status-badge status-normal">Active</span></td>
</tr>
<tr>
<td>Multivitamin</td>
<td>1 tablet PO</td>
<td>Daily</td>
<td>Nutritional support</td>
<td><span class="status-badge status-normal">Active</span></td>
</tr>
<tr>
<td>Ondansetron (Zofran)</td>
<td>8 mg PO</td>
<td>As needed</td>
<td>Nausea (residual)</td>
<td><span class="status-badge status-normal">PRN</span></td>
</tr>
</tbody>
</table>
<p style="margin-top: 15px; color: #718096; font-size: 14px;"><strong>Note:</strong> All chemotherapy medications discontinued after completion of 6 cycles of R-CHOP in May 2024.</p>
</div>
<!-- Follow-up Plan -->
<div class="section">
<h2>üìã Follow-up Plan</h2>
<h3 style="color: #2d3748; margin-top: 20px; margin-bottom: 15px;">DLBCL Surveillance (Post-Remission)</h3>
<div class="followup-list">
<ul>
<li>Clinical evaluation every 3 months for first 2 years</li>
<li>Then every 6 months for years 3-5</li>
<li>Then annually after 5 years</li>
<li>LDH with each visit</li>
<li>CT chest/abdomen/pelvis every 6 months for first 2 years (optional per NCCN)</li>
<li>PET/CT only if clinical suspicion of recurrence</li>
<li>Monitor for late effects of therapy (cardiac, secondary malignancies)</li>
<li>Echocardiogram annually for 5 years (anthracycline exposure)</li>
</ul>
</div>
<h3 style="color: #2d3748; margin-top: 25px; margin-bottom: 15px;">Next Scheduled Appointments</h3>
<div class="appointment-card">
<h4>Hematology-Oncology - February 15, 2025</h4>
<p><strong>Provider:</strong> Dr. Michael Chen, MD</p>
<p><strong>Purpose:</strong> 3-month surveillance visit, physical exam, labs (CBC, CMP, LDH)</p>
</div>
<div class="appointment-card">
<h4>Cardiology - January 2025</h4>
<p><strong>Provider:</strong> Dr. Emily Rodriguez, MD</p>
<p><strong>Purpose:</strong> Annual echocardiogram for anthracycline cardiotoxicity surveillance</p>
</div>
<div class="appointment-card">
<h4>Radiology - May 2025</h4>
<p><strong>Provider:</strong> Imaging Center</p>
<p><strong>Purpose:</strong> Surveillance CT chest/abdomen/pelvis (6-month interval)</p>
</div>
<div class="appointment-card">
<h4>Primary Care - March 2025</h4>
<p><strong>Provider:</strong> Dr. Lisa Thompson, MD</p>
<p><strong>Purpose:</strong> Annual physical, general health maintenance</p>
</div>
</div>
</div>
<div class="footer">
<p>Metropolitan Cancer Center | Department of Hematology-Oncology</p>
<p>This document contains protected health information (PHI) and is confidential.</p>
<p>Generated: 11/15/2024 19:15 | Report ID: EHR-2024-11-789321</p>
</div>
</div>
</body>
</html>
